Daily non-political popular news in brief.

OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients

06-02-2007 · EurekAlert!

The study showed that sipuleucel-T did not significantly delay the time it took for a patient's PSA to reach a value of 3 ng/ml, the primary endpoint of the study, but it did show a prolongation in prostate-specific antigen doubling time (PSADT).

Keywords: ohsu, cancer, institute, shows, findings, immunotherapy, vaccine, prostate, patients, show, finding, patient

« Previous | Next »

Similar news on "OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients":

From clinical cancer research: rethinking therapeutic cancer vaccine trials
07-03-2007 · EurekAlert!
Ongoing therapeutic cancer vaccine trials have yet to show evidence of vaccines spurring a patient's immune system to shrink tumors -- yet patients who receive these vaccines in trials tend to live longer and respond better to subsequent treatment. In the July 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, a team of National Cancer Institute researchers asks a fundamental question: are we looking at cancer vaccine trials the wrong way?
Similar news · Read more »
Positioning pelvic cancer patients on stomachs for radiation yields better results
10-28-2007 · EurekAlert!
Oregon Health & Science University Cancer Institute researchers have found that positioning pelvic cancer patients on their stomachs rather than their backs is a better method for delivering radiation therapy. Because patients return for multiple therapies, being able to reproduce the positioning of the patient allowed more precision, which reduces toxicity. "It was a surprising finding," according to according to Martin Fuss, M.D., the director of the Program in Image-Guided Radiation Therapy, OHSU Radiation Medicine.
Similar news · Read more »
Study shows endemic cholera can be controlled with oral vaccines
11-26-2007 · EurekAlert!
Endemic cholera, a potentially fatal diarrheal disease found in the world's most impoverished countries, could be effectively controlled by orally vaccinating half of the affected populations once every two years for only pennies per dose, according to new findings by an international team of researchers led by Ira M. Longini Jr., Ph.D., a biostatistician in the Vaccine and Infectious Disease Institute at Fred Hutchinson Cancer Research Center in Seattle.
Similar news · Read more »
Penn's Abramson Cancer Center part of major phase III study for myeloma
11-21-2007 · EurekAlert!
Researchers from the UPenn's Abramson Cancer Center announced today that findings from two international clinical trials show unprecedented survival for patients with myeloma, a cancer the blood-making cells of bone marrow. Findings show that with the oral drug lenalidomide, in combination with dexamethasone, patients significantly improved by all measures where previous treatments had failed -- including a median survival of nearly three years -- the longest median survival known for this difficult to treat patient group.
Similar news · Read more »
Annals of Internal Medicine tip sheet for March 20, 2007
03-19-2007 · EurekAlert!
The following articles are featured in the upcoming Annals of Internal Medicine: "Flexible Use of Drugs with Close Patient Follow-up Can Successfully Control Rheumatoid Arthritis;" "Osteoporosis Drug Strengthens Bones in Men with Prostate Cancer," and "Experts Show Physicians How to Initiate and Carry Through Timely and Effective Discussions about Hospice with Dying Patients."
Similar news · Read more »
Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy
06-04-2007 · EurekAlert!
The number of tumor cells circulating in the bloodstream of patients with metastatic, hormone-resistant, prostate cancer can predict how they will do with chemotherapy, according to results of an international trial. The findings, if backed by larger studies, could have important implications for designing personalized treatments for this very dangerous type of prostate cancer, says a Jefferson Medical College researcher and study first author.
Similar news · Read more »
VEGF Trap shows activity in patients with advanced ovarian cancer
06-02-2007 · EurekAlert!
Preliminary results of a randomized, international Phase II trial of VEGF Trap (aflibercept) show activity in patients with recurrent epithelial ovarian cancer (EOC) who had received three or four prior chemotherapy regimens and had become resistant to platinum-based chemotherapy agents. The findings, which are being presented today at the American Society of Clinical Oncology’s annual meeting, may indicate a role for this targeted therapy in women with ovarian cancer who have exhausted all other options.
Similar news · Read more »
5-year study shows Gleevec's potency against chronic myeloid leukemia
12-06-2006 · EurekAlert!
In a study of patients with chronic myeloid leukemia, some 95 percent have survived the cancer after five years due to treatment with Gleevec, according to results published this week in the New England Journal of Medicine. Howard Hughes Medical Institute investigator Brian Druker, who led the five-year study, said the findings demonstrate Gleevec's effectiveness against the formerly fatal disease.
Similar news · Read more »
OHSU Cancer Institute, 1 of largest in GIST study and Gleevec
04-12-2007 · EurekAlert!
Gleevec, a pill developed in conjunction with Oregon Health & Science University is again showing excellent results in preventing cancer recurrence in GIST patients after complete removal of their tumors.
Similar news · Read more »
Phase II study shows HRPC patients with bone metastases see improved survival with ZD4054
09-25-2007 · EurekAlert!
New Phase II data presented today suggest that ZD4054, a novel compound in development for the treatment of men with hormone-resistant prostate cancer, could offer a promising improvement in overall survival in men with metastatic HRPC who were asymptomatic or mildly symptomatic for pain.1 Patients who received ZD4054 10mg once-daily experienced a 45 percent reduction in the risk of death compared to placebo.
Similar news · Read more »